Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

(E-pub Ahead of Print)

Author(s): Chao Niu, Hunjun Xie, Haji Akber Aisa*

Journal Name: Mini-Reviews in Medicinal Chemistry


Become EABM
Become Reviewer
Call for Editor

Abstract:

The small-molecular inhibitors targeted JAks (JAK inhibitors), could modulate the cytokines-mediated signaling via JAK-STAT pathway, which plays a important role in immune regulation and cell proliferation. The JAK inhibitors are previously designed and synthesized to treat diseases involved with hematologic and immune system. Increasing evidence shows that they are quite effective in atopic dermatitis (AD), alopecia areata (AA), psoriasis, vitiligo, and other autoimmune-induced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in laboratory and clinically. In this view, we would like to summarize so we review the applications of these inhibitors with emphasis on profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literatures.

Keywords: JAK-STAT, JAK inhibitors, dermatologic conditions, vitiligo, tofacitinib, ruxolitinib

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 25 March, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1389557521666210325120233
Price: $95

Article Metrics

PDF: 220